PMID- 27859039
OWN - NLM
STAT- MEDLINE
DCOM- 20170529
LR  - 20181113
IS  - 1532-6535 (Electronic)
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 101
IP  - 2
DP  - 2017 Feb
TI  - Potential Psychiatric Uses for MDMA.
PG  - 194-196
LID - 10.1002/cpt.565 [doi]
AB  - Phase II trials of 3,4-methylenedioxymethamphetamine (MDMA)-assisted 
      psychotherapy have demonstrated initial safety and efficacy for treatment of 
      posttraumatic stress disorder (PTSD), with potential for expansion to depression 
      and anxiety disorders. In these trials, single doses of MDMA are administered in 
      a model of medication-assisted psychotherapy, differing from trials involving 
      daily drug administration without psychotherapy. This model presents an 
      opportunity to utilize accelerated regulatory pathways, such as the US Food and 
      Drug Administration (FDA) Breakthrough Therapy Designation, to most effectively 
      and expeditiously test such novel approaches.
CI  - (c) 2016, The Authors. Clinical Pharmacology & Therapeutics published by Wiley 
      Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and 
      Therapeutics.
FAU - Yazar-Klosinski, B B
AU  - Yazar-Klosinski BB
AD  - Multidisciplinary Association for Psychedelic Studies, Santa Cruz, California, 
      USA.
FAU - Mithoefer, M C
AU  - Mithoefer MC
AD  - Multidisciplinary Association for Psychedelic Studies, Santa Cruz, California, 
      USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Adrenergic Uptake Inhibitors)
RN  - 0 (Psychotropic Drugs)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Adrenergic Uptake Inhibitors/administration & dosage/*therapeutic use
MH  - Clinical Trials, Phase II as Topic
MH  - Humans
MH  - N-Methyl-3,4-methylenedioxyamphetamine/administration & dosage/*therapeutic use
MH  - Psychotherapy/*methods
MH  - Psychotropic Drugs/administration & dosage/*therapeutic use
MH  - Stress Disorders, Post-Traumatic/*therapy
MH  - United States
MH  - United States Food and Drug Administration
PMC - PMC5260336
EDAT- 2016/11/20 06:00
MHDA- 2017/05/30 06:00
PMCR- 2017/01/13
CRDT- 2016/11/19 06:00
PHST- 2016/08/12 00:00 [received]
PHST- 2016/10/31 00:00 [revised]
PHST- 2016/11/06 00:00 [accepted]
PHST- 2016/11/20 06:00 [pubmed]
PHST- 2017/05/30 06:00 [medline]
PHST- 2016/11/19 06:00 [entrez]
PHST- 2017/01/13 00:00 [pmc-release]
AID - CPT565 [pii]
AID - 10.1002/cpt.565 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 2017 Feb;101(2):194-196. doi: 10.1002/cpt.565.